Evidence map›Paper›PMID 35104370›Full record

SynthesisHematological oncology2022

Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.

Elizaveta Belyaeva, Ayelet Rubenstein, Sheila K Pierson, Delaney Dalldorf, Dale Frank, Megan S Lim, David C Fajgenbaum

Registry-linked trialOpen access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Hematological oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02817997 recruitingnot on this map

ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease

Typeobservational_patient_registrySponsorUniversity of PennsylvaniaRan2016 to 2027Enrolled1,000ConditionsCastleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Thrombocytopenia, anasarca, and severe inflammation.American journal of hematology · 2022
    Article
  11. How we manage idiopathic multicentric Castleman disease.Clinical advances in hematology & oncology : H&O · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Elizaveta BelyaevaDepartment of Pathology and Laboratory Medicine, Tulane University, New Orleans, Louisiana, USA.
Ayelet RubensteinDepartment of Medicine, Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sheila K PiersonDepartment of Medicine, Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-3736-1411
Delaney DalldorfCastleman Disease Collaborative Network, Philadelphia, Pennsylvania, USA.
Dale FrankDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-6919-868X
Megan S LimDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-0415-2867
David C FajgenbaumDepartment of Medicine, Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-7367-8184
University of Pennsylvania · USCollaborative Group (United States) · USTulane University · US

Funding

mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
Castleman's Awareness & Research Effort/Castleman Disease Collaborative NetworkNHLBI NIH HHS R01 HL141408NHLBI NIH HHS R01HL141408
6 · The paper itself

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a polyclonal lymphoproliferative disorder characterized by constitutional symptoms, generalized lymphadenopathy, cytopenias, and multi-organ dysfunction due to excessive cytokines, notably Interleukin-6. Idiopathic multicentric Castleman disease is often sub-classified into iMCD-TAFRO, which is associated with thrombocytopenia (T), anasarca (A), fever/elevated C-reactive protein (F), renal dysfunction (R), and organomegaly (O), and iMCD not otherwise specified (iMCD-NOS), which is typically associated with thrombocytosis and hypergammaglobulinemia. The diagnosis of iMCD is challenging as consensus clinico-pathological diagnostic criteria were only recently established and include several non-specific lymph node histopathological features. Identification of further clinico-pathological features commonly found in iMCD could contribute to more accurate and timely diagnoses. We set out to characterize bone marrow (BM) histopathological features in iMCD, assess differences between iMCD-TAFRO and iMCD-NOS, and determine if these findings are specific to iMCD. Examination of BM specimens from 24 iMCD patients revealed a high proportion with hypercellularity, megakaryocytic atypia, reticulin fibrosis, and plasmacytosis across patients with both iMCD-NOS and iMCD-TAFRO with significantly more megakaryocytic hyperplasia (p = 0.001) in the iMCD-TAFRO cases. These findings were also consistent with BM findings from 185 published cases of iMCD-NOS and iMCD-TAFRO. However, these findings are relatively nonspecific as they can be seen in various other infectious, malignant, and autoimmune diseases.

Indexed as

Castleman DiseaseThrombocytopeniaBone MarrowFeverHumansLymph Nodesbone marrowcastleman diseaseiMCDmegakaryocytic hyperplasiaplasmacytosisreticulin fibrosis

Identifiers

PMID35104370
PMCPMC9547646
OpenAlexW4210429301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.